Evaluation of real-world evidence to assess health outcomes related to deprescribing medications in older adults: an International Society for Pharmacoepidemiology–endorsed systematic review of methodology - Takeaways - MDSpire

Evaluation of real-world evidence to assess health outcomes related to deprescribing medications in older adults: an International Society for Pharmacoepidemiology–endorsed systematic review of methodology

  • By

  • Kaleen N Hayes

  • Joshua David Niznik

  • Danijela Gnjidic

  • Frank Moriarty

  • Nha Tran

  • Antoinette B Coe

  • Andrew R Zullo

  • Sirui Zhang

  • Matthew Alcusky

  • Dimitri Bennett

  • Sirpa Hartikainen

  • Marie-Laure Laroche

  • Xiaojuan Li

  • Joshua K Lin

  • Jennifer L Lund

  • Maurizio Sessa

  • Shahar Shmuel

  • Caroline Sirois

  • Denis Talbot

  • Miia Tiihonen

  • Xuerong Wen

  • Mouna J Sawan

  • Daniela C Moga

  • November 4, 2024

  • 0 min

Share

  • 1

    The systematic review analyzed observational studies using real-world data to evaluate the health effects of medication deprescribing in older adults.

  • 2

    Forty-five studies were included, covering various drug classes, with most adequately addressing potential time-related biases.

  • 3

    Twelve studies lacked a clear definition of deprescribing, and there was significant heterogeneity in how deprescribing duration was defined.

  • 4

    Observational studies face challenges such as misclassification of deprescribing and biases like confounding by indication and selection bias.

  • 5

    The review highlights the need for minimum reporting criteria to enhance the transparency and quality of future deprescribing research.

Original Source(s)

Evaluation of real-world evidence to assess health outcomes related to deprescribing medications in older adults: an International Society for Pharmacoepidemiology–endorsed systematic review of methodology

  • by Kaleen N Hayes, Joshua David Niznik, Danijela Gnjidic, Frank Moriarty, Nha Tran, Antoinette B Coe, Andrew R Zullo, Sirui Zhang, Matthew Alcusky, Dimitri Bennett, Sirpa Hartikainen, Marie-Laure Laroche, Xiaojuan Li, Joshua K Lin, Jennifer L Lund, Maurizio Sessa, Shahar Shmuel, Caroline Sirois, Denis Talbot, Miia Tiihonen, Xuerong Wen, Mouna J Sawan, Daniela C Moga

  • November 4, 2024

Related Content

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

CKD Markers Linked to Cognitive Risk

In adults with chronic kidney disease, higher proteinuria and lower estimated glomerular filtration rate are associated with increased risk of incident cognitive impairment.

Prediction model for depression risk in middle-aged and elderly patients with metabolic syndrome: a nomogram and interpretable machine learning approach based on CHARLS